A phase II trial of MK-3475 in patients with non-small cell lung cancer with a performance status of 2 (PePS2)

Billingham, Lucinda (Co-Investigator)
Middleton, Gary (Principal Investigator)

Short title	A phase II trial of MK-3475 in patients with non-small cell lung cancer with a performance status of 2 (PePS2)
Status	Active
Effective start/end date	21/10/15 → 31/12/24

Funding

MERCK LIMITED

1 Article

Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
Middleton, G., Brock, K., Savage, J., Mant, R., Summers, Y., Connibear, J., Shah, R., Ottensmeier, C., Shaw, P., Lee, S. M., Popat, S., Barrie, C., Barone, G. & Billingham, L., Sept 2020, In: The Lancet Respiratory Medicine. 8, 9, p. 895-904 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
32 Citations (Scopus)

207 Downloads (Pure)